Literature DB >> 1786555

Sensitization of mesolimbic brain stimulation reward after electrical kindling of the amygdala.

L Kokkinidis1, T B Borowski.   

Abstract

The effects of partial kindling of the central amygdaloid nucleus on brain stimulation reward were evaluated. Intracranial self-stimulation (ICSS) rate intensity functions were determined using a two-hole nose-poke discrimination paradigm in rats implanted with electrodes in the A10 dopamine (DA) neuronal region of the ventral tegmental area (VTA), and in the medial forebrain bundle (MFB) at the level of the lateral hypothalamus. The kindling process did not influence ICSS baseline rates from either site. However, following stage 4 kindling, a low dose amphetamine challenge increased ICSS, resulted in a significant shift to the left of the rate intensity functions, and decreased reward thresholds. Analysis of the error scores which consisted of nonreinforced responses made during ICSS testing revealed that the interaction between kindling and amphetamine on ICSS was specific to changes in central reward processes, and could not be attributed to the influence of rate-enhancing performance variables. The kindling-elicited sensitization of mesolimbic DA reward functioning seen after amphetamine challenge was discussed in relation to the role of the central amygdala in the integration of stimulus-reward associations, and in the conditioning of affective emotional states.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1786555     DOI: 10.1016/0361-9230(91)90210-b

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  2 in total

1.  Kindling modifies morphine, cocaine and ethanol place preference.

Authors:  Axel Becker; Marco Schmitz; Gisela Grecksch
Journal:  Exp Brain Res       Date:  2005-08-11       Impact factor: 1.972

Review 2.  The central amygdala as an integrative hub for anxiety and alcohol use disorders.

Authors:  Nicholas W Gilpin; Melissa A Herman; Marisa Roberto
Journal:  Biol Psychiatry       Date:  2014-09-22       Impact factor: 13.382

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.